The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology

Gene

Volumn 573, Issue 2, 2015, Pages 177-187

  Veerman, Christiaan C ^a   Wilde, Arthur A M ^a   Lodder, Elisabeth M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL NAV1.5; ISOPROTEIN; SCN5A PROTEIN, HUMAN;

ATRIAL FIBRILLATION; BRUGADA SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DRUG TARGETING; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE POTENTIAL; HUMAN; LONG QT SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; POPULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SCN5A GENE; SICK SINUS SYNDROME; SODIUM CURRENT; TRANSCRIPTION REGULATION; ACTION POTENTIAL; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HEART CONTRACTION; HEART DISEASE; MUTATION;

ACTION POTENTIALS; ANIMALS; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; MUTATION; MYOCARDIAL CONTRACTION; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PROTEIN ISOFORMS;

EID: 84941932690     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.08.062     Document Type: Review

References (136)

1. Abe K., et al. Sodium channelopathy underlying familial sick sinus syndrome with early onset and predominantly male characteristics. Circ. Arrhythm. Electrophysiol. 2014, 7(3):511-517.
2. v1.5 and interacting proteins: physiology and pathophysiology. J. Mol. Cell. Cardiol. 2010, 48(1):2-11.
3. Ackerman M.J., et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 2001, 286(18):2264-2269.
4. Akai J., et al. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 2000, 479(1-2):29-34.
5. Albert C.M., et al. Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation 2008, 117(1):16-23.
6. Alves L.E., Buser J.W., Rose E.P. Cardiomyopathy due to chronic tachycardias. JAMA 1985, 253(21):3092.
7. Arnolds D.E., et al. TBX5 drives Scn5a expression to regulate cardiac conduction system function. J. Clin. Invest. 2012, 122(7):2509-2518.
8. Attwell D., et al. The steady state TTX-sensitive ("window") sodium current in cardiac Purkinje fibres. Pflugers Arch. - Eur. J. Physiol. 1979, 379(2):137-142.
9. Balser J.R. The cardiac sodium channel: gating function and molecular pharmacology. J. Mol. Cell. Cardiol. 2001, 33(4):599-613.
10. V1.5 channel function. Br. J. Anaesth. 2014, 113(Suppl.):i39-i48.
11. V1.5 cardiac sodium channel resulting in atrial standstill and His-Purkinje system disease. J. Pediatr. 2014, 165(5):1050-1052.
12. Benson D.W., et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Investig. 2003, 112(7):1019-1028.
13. Besson P., et al. How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells?. Biochim. Biophys. Acta Biomembr. 2015.
14. + channel mutation causing both long-QT and Brugada syndromes. Circ. Res. 1999, 85(12):1206-1213.
15. Bezzina C.R., et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ. Res. 2003, 92(2):159-168.
16. v1.5 sodium channels in macrophages in multiple sclerosis lesions. Mult. Scler. (Houndmills, Basingstoke, England) 2013, 19(5):532-542.
17. V1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene 2011, 30(17):2070-2076.
18. Buchanan J.W., Saito T., Gettes L.S. The effects of antiarrhythmic drugs, stimulation frequency, and potassium-induced resting membrane potential changes on conduction velocity and dV/dtmax in guinea pig myocardium. Circ. Res. 1985, 56(5):696-703.
19. + channel (SCN5A) mutations and impaired cardiac pacemaking in sick sinus syndrome. Circ. Res. 2010, 107(1):126-137.
20. V1.5 and β3 subunit. J. Mol. Cell. Cardiol. 2014, 74:297-306.
21. Catterall W.a. Sodium channels, inherited epilepsy, and antiepileptic drugs. Annu. Rev. Pharmacol. Toxicol. 2014, 54:317-338.
22. Cerrone M., et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation 2014, 129(10):1092-1103.
23. Chambers J.C., et al. Genetic variation in SCN10A influences cardiac conduction. Nat. Genet. 2010, 42(2):149-152.
24. Chen Q., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998, 392(6673):293-296.
25. + channel function, regulation, structure, trafficking and sequestration. J. Physiol. 2015, 593(6):1347-1360. 10.1113/jphysiol.2014.281428.
26. V1.5 voltage-gated Na+ channel "neonatal" splice form. J. Neurosci. Methods 2005, 147(2):88-98.
27. + channels: an original mechanism of arrhythmia. Circulation 2003, 107(17):2233-2237.
28. Coronel R., et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005, 112(18):2769-2777.
29. Courtney K.R. Slow sodium channel inactivation and the modulated receptor hypothesis application to phenobarbital. Biochim. Biophys. Acta Biomembr. 1981, 642(2):433-437.
30. Crotti L., et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for brugada syndrome genetic testing: implications for genetic testing. J. Am. Coll. Cardiol. 2012, 60(15):1410-1418.
31. Daimi H., et al. Regulation of SCN5A by microRNAs: miR-219 modulates SCN5A transcript expression and the effects of flecainide intoxication in mice. Heart Rhythm. 2015, 12(6):1333-1342.
32. Darbar D., et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008, 117(15):1927-1935.
33. De Ferrari G.M., et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 2015, 12(5):872-878.
34. De Groot S.H., et al. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed afterdepolarization-dependent ventricular arrhythmias. Circulation 2000, 102(17):2145-2151.
35. Delmar M. The intercalated disk as a single functional unit. Heart Rhythm. 2004, 1(1):12-13.
36. Ellinor P.T., et al. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm. 2008, 5(1):99-105.
37. Exome Aggregation Consortium ExAC database 2015, MA ExAC, Cambridge. http://exac.broadinstitute.org.
38. Frigo G., et al. Homozygous SCN5A mutation in Brugada syndrome with monomorphic ventricular tachycardia and structural heart abnormalities. Europace 2007, 9(6):391-397.
39. Gaunt T.R., et al. Integration of genetics into a systems model of electrocardiographic traits using HumanCVD BeadChip. Circ. Cardiovasc. Genet. 2012, 5(6):630-638.
40. Gellens M.E., et al. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(2):554-558.
41. Gosselin-Badaroudine P., et al. A proton leak current through the cardiac sodium channel is linked to mixed arrhythmia and the dilated cardiomyopathy phenotype. PLoS One 2012, 7(5).
42. Groome J.R. Voltage gated sodium channels. Handb. Exp. Pharmacol. 2014, 221:7-32.
43. Gui J., et al. Mutation-specific effects of polymorphism H558R in SCN5A-related sick sinus syndrome. J. Cardiovasc. Electrophysiol. 2010, 21(5):564-573.
44. Gupta T., et al. Antiarrhythmic properties of ranolazine: a review of the current evidence. Int. J. Cardiol. 2015, 187:66-74.
45. Herren A.W., Bers D.M., Grandi E. Post-translational modifications of the cardiac Na channel: contribution of CaMKII-dependent phosphorylation to acquired arrhythmias. American Journal of Physiology. Am. J. Physiol. Heart Circ. Physiol. 2013, 305(4):H431-H445.
46. Holm A.N., et al. Sodium current in human jejunal circular smooth muscle cells. Gastroenterology 2002, 122(1):178-187.
47. Holm H., et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat. Genet. 2010, 42(2):117-122.
48. Hoogendijk M.G., et al. ST segment elevation by current-to-load mismatch: an experimental and computational study. Heart Rhythm. 2011, 8(1):111-118.
49. NHLBI GO Exome Sequencing Project (ESP), Exome Variant Server., p. http://evs.gs.washington.edu/EVS/.
50. Hu D., et al. A mutation in the beta-3 subunit of the cardiac sodium channel associated with brugada ECG phenotype. Circ. Cardiovasc. Genet. 2009, 2(3):270-278.
51. V1.5 channels. American Journal of Physiology. Am. J. Physiol. Heart Circ. Physiol. 2011, 300(1):H288-H299.
52. Jeff J.M., et al. SCN5A variation is associated with electrocardiographic traits in the Jackson Heart Study. Circ. Cardiovasc. Genet. 2011, 4(2):139-144.
53. Jeff J.M., et al. Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans. Ann. Hum. Genet. 2013, 77(4):321-332.
54. Kapa S., et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009, 120(18):1752-1760.
55. V1.5 cardiac sodium channel. Circ. Cardiovasc. Genet. 2015.
56. + channel inactivation gate during inactivation. J. Biolumin. Chemilumin. 1996, 271(48):30971-30979.
57. Laitinen-Forsblom P.J., et al. SCN5A mutation associated with cardiac conduction defect and atrial arrhythmias. J. Cardiovasc. Electrophysiol. 2006, 17(5):480-485.
58. Laurent G., et al. Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. J. Am. Coll. Cardiol. 2012, 60(2):144-156.
59. Lei M., et al. Requirement of neuronal- and cardiac-type sodium channels for murine sinoatrial node pacemaking. J. Physiol. 2004, 559(Pt. 3):835-848.
60. Lei M., et al. Sinus node dysfunction following targeted disruption of the murine cardiac sodium channel gene Scn5a. J. Physiol. 2005, 567(Pt. 2):387-400.
61. Lippi G., et al. Genetic and clinical aspects of Brugada syndrome: an update. Adv. Clin. Chem. 2012, 56:197-208.
62. Lodder E.M., Bezzina C.R. Genomics of Cardiac Electrical Function. Brief. Funct. Genomics 2013.
63. Lodder E.M., Wilde A.A.M. Clinical assessment of the pathogenicity of unknown variants in long-QT syndrome: does the pendulum swing back?. J. Cardiovasc. Electrophysiol. 2012, 23(6):643-644.
64. Lopez K.N., et al. Homozygous mutation in SCN5A associated with atrial quiescence, recalcitrant arrhythmias, and poor capture thresholds. Heart Rhythm. 2011, 8(3):471-473.
65. Luchsinger J.a., Steinberg J.S. Resolution of cardiomyopathy after ablation of atrial flutter. J. Am. Coll. Cardiol. 1998, 32(1):205-210.
66. Lupoglazoff J.M., et al. Homozygotous mutation of the SCN5A gene responsible for congenital Long QT syndrome with 2/1 atrioventricular block 2002.
67. Makielski J.C., et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ. Res. 2003, 93(9):821-828.
68. Makita N., et al. Congenital atrial standstill associated with coinheritance of a novel SCN5A mutation and connexin 40 polymorphisms. Heart Rhythm. 2005, 2(10):1128-1134.
69. Makiyama T., et al. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J. Am. Coll. Cardiol. 2008, 52(16):1326-1334.
70. Maltsev V.a., et al. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998, 98(23):2545-2552.
71. Mann S.A., et al. R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 2012, 60(16):1566-1573.
72. Mao W., et al. Reactive oxygen species suppress cardiac NaV1.5 expression through Foxo1. PLoS One 2012, 7(2):e32738.
73. V1.5 by post-translational modifications. J. Mol. Cell. Cardiol. 2015, 82:36-47. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022282815000589.
74. Marsman R.F., Tan H.L., Bezzina C.R. Genetics of sudden cardiac death caused by ventricular arrhythmias. Nature Reviews. Cardiology 2013, 11(2):96-111.
75. McNair W.P., et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004, 110(15):2163-2167.
76. Meadows L.S., Isom L.L. Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes. Cardiovasc. Res. 2005, 67(3):448-458.
77. Medeiros-Domingo A., et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007, 116(2):134-142.
78. Milne J.R., et al. Class 1 antiarrhythmic drugs-characteristic electrocardiographic differences when assessed by atrial and ventricular pacing. Eur. Heart J. 1984, 5(2):99-107.
79. Mizusawa Y., Horie M., Wilde A.A. Genetic and clinical advances in congenital Long QT syndrome. Circ. J. 2014, 78(12):2827-2833.
80. V1.5 mutations in patients with mixed arrhythmias and dilated cardiomyopathy. J. Gen. Physiol. 2015, 145(2):93-106.
81. Moss A.J., et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol. 2008, 19(12):1289-1293.
82. Murdock D.K., Kaliebe J., Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin. Electrophysiol. 2012, 35(3):302-307.
83. Nair K., et al. Escape capture bigeminy: phenotypic marker of cardiac sodium channel voltage sensor mutation R222Q. Heart Rhythm. 2012, 9(10):1681-1688.
84. Nakajima S., et al. A novel SCN5A mutation demonstrating a variety of clinical phenotypes in familial sick sinus syndrome. Intern. Med. (Tokyo, Japan) 2013, 52(16):1805-1808.
85. Napolitano C. The contradictory genetics of atrial fibrillation: the growing gap between knowledge and clinical implications. J. Cardiovasc. Electrophysiol. 2013, 1-3.
86. Neu A., et al. A homozygous SCN5A mutation in a severe, recessive type of cardiac conduction disease. Hum. Mutat. 2010, 31(8):1609-1621.
87. Nguyen T.P., et al. Divergent biophysical defects caused by mutant sodium channels in dilated cardiomyopathy with arrhythmia. Circ. Res. 2008, 102(3):364-371.
88. Nikulina S.Y., et al. An investigation of the association of the H558R polymorphism of the SCN5A gene with idiopathic cardiac conduction disorders. Genet. Test. Mol. Biomarkers 2015, 19(6). (p.150414120233001).
89. Noseworthy P.a., et al. Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study. Circ. Cardiovasc. Genet. 2011, 4(3):305-311.
90. Nuss H.B., et al. Functional association of the beta 1 subunit with human cardiac (hH1) and rat skeletal muscle (mu 1) sodium channel alpha subunits expressed in Xenopus oocytes. J. Gen. Physiol. 1995, 106(6):1171-1191.
91. Olson T.M., et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005, 293(4):447-454.
92. V1.5: an electrophysiological comparison of "neonatal" and "adult" isoforms and critical involvement of a lysine residue. J. Cell. Physiol. 2008, 216(3):716-726.
93. + channel chimaeras. J. Physiol. 1999, 515(Pt. 1):61-73.
94. Pittman A.M., et al. Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet. 2010, 6(9).
95. Plant L.D., et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J. Clin. Investig. 2006, 116(2):430-435.
96. Probst V., et al. SCN5A mutations and the role of genetic background in the pathophysiology of brugada syndrome. Circ. Cardiovasc. Genet. 2009, 2(6):552-557.
97. Remme C.A. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects. J. Physiol. 2013, 591(Pt 17):4099-4116.
98. Remme C.A., Wilde A.A.M. Targeting sodium channels in cardiac arrhythmia. Curr. Opin. Pharmacol. 2014, 15:53-60.
99. Remme C.A., et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006, 114(24):2584-2594.
100. Remme C.A., et al. The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium. Basic Res. Cardiol. 2009, 104(5):511-522.
101. Ritchie M.D., et al. Genome- and phenome-wide analysis of cardiac conduction identifies markers of arrhythmia risk. Circulation 2013, 127(13):1377-1385.
102. Rossenbacker T., et al. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death. Heart Rhythm. 2004, 1(5):610-615.
103. Sakmann B.F., et al. Distribution of a persistent sodium current across the ventricular wall in guinea pigs. Circ. Res. 2000, 87(10):910-914.
104. Schott J.J., et al. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet. 1999, 23(1):20-21.
105. V1.5. J. Mol. Cell. Cardiol. 2010, 49(1):16-24.
106. Schwartz P.J., et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N. Engl. J. Med. 2000, 343(4):262-267.
107. Shang L.L., Dudley S.C. Tandem promoters and developmentally regulated 5'- and 3'-mRNA untranslated regions of the mouse Scn5a cardiac sodium channel. J. Biolumin. Chemilumin. 2005, 280(2):933-940.
108. Shang L.L., et al. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am. J. Physiol. Cell Physiol. 2008, 294(1):C372-C379.
109. Smith J.G., et al. Genome-wide association study of electrocardiographic conduction measures in an isolated founder population: Kosrae. Heart Rhythm. 2009, 6(5):634-641.
110. Smith J.G., et al. Genome-wide association studies of the PR interval in African Americans. PLoS Genet. 2011, 7(2):e1001304.
111. Smits J.P.P., et al. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J. Mol. Cell. Cardiol. 2005, 38(6):969-981.
112. Sotoodehnia N., et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat. Genet. 2010, 42(12):1068-1076.
113. Splawski I., et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (New York, N.Y.) 2002, 297(5585):1333-1336.
114. Swan H., et al. Gain-of-function mutation of the SCN5A gene causes exercise-induced polymorphic ventricular arrhythmias. Circ. Cardiovasc. Genet. 2014, 7(6):771-781.
115. Syrris P., et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006, 113(3):356-364.
116. Tan B.H., et al. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm. 2005, 2(7):741-747.
117. Tan H.L., et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001, 409(6823):1043-1047.
118. Tester D.J., et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005, 2(5):507-517.
119. Van Den Boogaard M., et al. Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer. J. Clin. Investig. 2012, 122(7):2519-2530.
120. Van Den Boogaard M., et al. A common genetic variant within SCN10A modulates cardiac SCN5A expression. J. Clin. Investig. 2014, 124(4):1844-1852.
121. Van Stuijvenberg L., et al. Alternative promoter usage and splicing of the human SCN5A gene contribute to transcript heterogeneity. DNA Cell Biol. 2010, 29(10):577-587.
122. Veldkamp M.W., et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ. Res. 2003, 92(9):976-983.
123. v1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ. Res. 2012, 111(3):333-343.
124. Viswanathan P.C., Benson D.W., Balser J.R. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J. Clin. Invest. 2003, 111(3):341-346.
125. Wang Q., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80(5):805-811.
126. Wang Q., et al. The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel. J. Med. Genet. 2004, 41(5):e66.
127. Watanabe H., et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Invest. 2008, 118(6):2260-2268.
128. Watanabe H., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat. Med. 2009, 15(4):380-383.
129. Watanabe H., et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ. Arrhythm. Electrophysiol. 2011, 4(6):874-881.
130. Watanabe H., et al. SCN5A mutation associated with ventricular fibrillation, early repolarization, and concealed myocardial abnormalities. Int. J. Cardiol. 2013, 165(2):e21-e23.
131. Weidmann S. The effect of the cardiac membrane potential on the rapid availability of the sodium-carrying system. J. Physiol. 1955, 127(1):213-224.
132. +-channel inactivation. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(22):10910-10914.
133. V1.5 in human brain astrocytoma and its effect on proliferation, invasion and apoptosis of astrocytoma cells. Oncol. Rep. 2014, 31(6):2692-2700.
134. Yang P., Kupershmidt S., Roden D.M. Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc. Res. 2004, 61(1):56-65.
135. Zaza A., Belardinelli L., Shryock J.C. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol. Ther. 2008, 119(3):326-339.
136. Zoni-Berisso M., et al. Epidemiology of atrial fibrillation: European perspective. J. Clin. Epidemiol. 2014, 6:213-220.